{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.5","upperLimit":"97.3","value":"94.6"},{"groupId":"OG001","lowerLimit":"82.7","upperLimit":"97.4","value":"92.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"64"}],"units":"Participants"}],"description":"Response criteria for CHR is reported as WBC≤institutional upper limit of normal, platelets\\<450,000/mm\\^3, no blasts or promyelocytes in peripheral blood, \\<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \\<5%, no extramedullary involvement (including no hepatomegaly or splenomegaly).","dispersionType":"95% Confidence Interval","groups":[{"description":"CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort A: CP-CML R-I"},{"description":"CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort B: CP-CML With T315I Mutation"}],"paramType":"NUMBER","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts A and B only.","reportingStatus":"POSTED","timeFrame":"Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose)","title":"Percentage of CP-CML Participants With CHR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}